Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Optimizing AAV9 Capsid Selection and Promoter Choice for CNS-Targeted Gene Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES.

Optimizing AAV9 Capsid Selection and Promoter Choice for CNS-Targeted Gene Therapies

Optimizing AAV9 Capsid and Promoter Design for CNS-Targeted Therapies

CELL & GENE | RNA | BIOLOGICS

A promotional graphic for Franklin BioLabs showcasing a list of their notable scientific publications in preclinical and translational research.

Selecting an appropriate AAV9 vector construct is a primary determinant of success for advanced therapeutics and complex biologics targeting the central nervous system (CNS). Applying proven intelligence in vector design and preclinical toxicology is how programs achieve predictable, 18-24 month IND timelines. An unmodified AAV9 capsid paired with a ubiquitous promoter often results in significant off-target expression, particularly in the liver, complicating the interpretation of IND-enabling toxicology studies and presenting a potential safety issue.

Frequently Asked Questions

    Why is AAV9 a common choice for CNS gene therapy?

    AAV9 is known for its ability to cross the blood-brain barrier and achieve broad transduction within the CNS, making it a valuable starting point for therapies targeting neurological disorders. Its clinical validation provides a strong regulatory precedent.

    What are the main risks of using a standard AAV9 vector?

    The primary risk is off-target biodistribution. AAV9 possesses a natural tropism for peripheral tissues like the liver and heart due to its interaction with specific cell surface glycans. This can lead to unintended biological activity and toxicity, which complicates safety assessments.

    How does promoter choice impact the safety profile?

    A strong, non-specific promoter (e.g., CMV, CAG) will drive high levels of transgene expression in any tissue the vector transduces. When combined with AAV9’s natural biodistribution, this can amplify off-target effects. A tissue-specific promoter is a key tool for restricting expression to the intended CNS targets.

    What is the role of capsid engineering in de-risking a program?

    Capsid engineering involves modifying the viral protein shell to alter its tropism. By modulating the capsid’s binding affinity for certain receptors, such as galactose, it is possible to detarget the liver and enhance transduction in the desired tissue, creating a more favorable safety and efficacy profile.

A Data-Driven Approach to Vector Design

A one-size-fits-all preclinical template does not exist for viral vector-based therapies. The initial vector construct, encompassing both the capsid and the promoter cassette, dictates the entire preclinical strategy. Our approach begins with a deep analysis of the target indication and the intended biological outcome to inform these design choices.

Recent work in modulating AAV9 galactose binding demonstrates that specific capsid variants can be engineered to reduce liver tropism and improve biodistribution (PMID: 39001819). This principle of rational capsid design is fundamental to minimizing clinical risk before the first GLP-compliant evaluations are initiated.

A marketing fact sheet from Franklin Biolabs about the scientific benefits of Mauritian cynomolgus macaques for preclinical research, featuring a photo of the primates.

The Importance of Translational Models

The same research highlights that species-specific differences in glycan presentation exist between preclinical models. This finding underscores the necessity of selecting a translational model with biology that closely mirrors the human response. Generating pivotal biodistribution and toxicology data in the most relevant system is a foundational component of a successful IND submission.

This philosophy of operating as an embedded scientific extension of a client’s team is a core principle of our scientific leadership. The long-standing collaborative relationships our team has cultivated are a testament to this approach. As Dr. Gerald S. Lipshutz noted of his work with our scientific leadership, “It really has been one of collaboration… They’ve really been a scientific partner… In my own words I would say that the quality of the people has really led to the quality of their product.” This methodology has contributed to our core team’s track record, which includes a 100% successful IND rate since 2019.

By integrating capsid selection, promoter optimization, and phase-appropriate model selection, we build a cohesive and data-driven path to IND.

Return to Vector | CMC | Analytics Services Hub

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities